Article Text

Download PDFPDF

Research
Impact and cost-effectiveness of formal gastroenterology outpatient referral Clinical Assessment Service
Free
  1. Stavroula Pelitari1,
  2. Charlotte Hathaway1,
  3. Dean Gritton1,
  4. Andrea Smith2,
  5. David Bush2,
  6. Shyam Menon1,
  7. Brian McKaig1
  1. 1 Department of Gastroenterology, Royal Wolverhampton NHS Trust, Wolverhampton, UK
  2. 2 Wolverhampton CCG, Wolverhampton Clinical Commissioning Group, Wolverhampton, UK
  1. Correspondence to Dr Brian McKaig, Department of Gastroenterology, The Royal Wolverhampton NHS Trust, New Cross Hospital, Wolverhampton, West Midlands WV10 0QP, UK; brian.mckaig{at}nhs.net

Abstract

Objective The aim was to assess the financial and operational impact of our new gastroenterology referral pathway model on our services.

Design An electronic ‘Clinical Assessment Service’ (CAS) proforma and an information platform were developed, and all data were analysed retrospectively.

Setting Royal Wolverhampton NHS Trust.

Patients 14 245 general practitioner (GP) referrals were received during January 2014–December 2016 with 9773 of them being triaged via our CAS.

Main outcome measures We looked into patients’ clinical outcome along with departmental performance and finances.

Results A new outpatient appointment was offered to 60.1% (n=5873) of the CAS referred patients. Endoscopic or radiological investigations were requested for 29.2% (n=2854) of patients prior to deciding on further management plan. Out of those, 27% (n=765) went on to receive another gastroenterology (GI) clinic appointment. The remaining 21.3% (n=2089) of the CAS patients were discharged back to their GP following initial investigations. 5.5% (n=538) were discharged back to primary care with a letter of advice, whereas 5.2% (n=509) were deemed inappropriate for GI clinic and were redirected to other specialists. Overall, 32% (n=3127) of patients were managed without a face to face consultation in the GI clinic. This corresponds to 3136 less outpatient appointments with estimated reduced expenditure by the Clinical Commissioning Group (CCG) of £481K. The 18-week performance and waiting times remained stable despite the increasing referral population. The DNA rate dropped from 14% pre to 8.5%.

Conclusions Our clinical assessment model has, in addition to the clinical benefits, a considerable positive financial impact to the health economy.

  • clinical decision making

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors SP conducted and submitted the study. CH, DG, AS and DB planned the study. SM planned and conducted the study. BM planned, conducted and submitted the study.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.